ACSL4 serves as a novel prognostic biomarker correlated with immune infiltration in Cholangiocarcinoma

Cholangiocarcinoma (CHOL) is the second most common primary hepatic malignant tumor, following hepatocellular carcinoma (HCC). CHOL is highly aggressive and heterogeneous resulting in poor prognosis.